Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 12/1/2016 |
| Start Date: | July 2015 |
| End Date: | November 2017 |
| Contact: | Aimee Talleur, MD |
| Email: | referralinfo@stjude.org |
| Phone: | 866-278-5833 |
Analysis of KIR+CD56+ T Cells and FcRg-CD56+CD3- NK Cells in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients and Donors
Viral infections and reactivation during pediatric allogeneic hematopoietic stem cell
transplantation (HSCT) are a common occurrence and significantly contribute to
post-transplant morbidity and mortality. The risk is high due to prolonged periods of immune
deficiency while awaiting immune reconstitution post-transplant. Current strategies to
reduce complications from viral infections include prophylactic treatment, close monitoring
for viral infections and prompt treatment at the first sign of symptoms or increasing viral
load. However, the most definitive treatment for viral infections remains the host's
cellular defenses. Improved understanding of the immune systems response to viral infections
may lead to better treatment strategies.
This study is being done to explore the relationships between T-cells and NK cells
(infection fighting cells) and viral infections or reactivations in young allogeneic stem
cell transplant patients. The investigators will be looking at how these cells react and
function in young patients receiving allogeneic stem cell transplantation, as well as in
healthy stem cell donors.
transplantation (HSCT) are a common occurrence and significantly contribute to
post-transplant morbidity and mortality. The risk is high due to prolonged periods of immune
deficiency while awaiting immune reconstitution post-transplant. Current strategies to
reduce complications from viral infections include prophylactic treatment, close monitoring
for viral infections and prompt treatment at the first sign of symptoms or increasing viral
load. However, the most definitive treatment for viral infections remains the host's
cellular defenses. Improved understanding of the immune systems response to viral infections
may lead to better treatment strategies.
This study is being done to explore the relationships between T-cells and NK cells
(infection fighting cells) and viral infections or reactivations in young allogeneic stem
cell transplant patients. The investigators will be looking at how these cells react and
function in young patients receiving allogeneic stem cell transplantation, as well as in
healthy stem cell donors.
PRIMARY OBJECTIVE:
- To explore the expansion patterns of KIR+CD56+ T-cells and FcRg-CD56+CD3- NK cells in
response to viral infection and reactivation in pediatric allogeneic hematopoietic stem
cell transplant (HSCT) patients.
SECONDARY OBJECTIVES:
- To describe the phenotype of KIR+CD56+ T-cells and FcRg-CD56+CD3- NK cells in pediatric
allogeneic HSCT patients and healthy donors.
- To describe the specificity and functional capacity of KIR+CD56+ T-cells against viral
antigens in both pediatric allogeneic HSCT patients and healthy donors.
- To describe the functional capacity of FcRg-CD56+CD3- NK cells against CMV-infected
cells in both pediatric allogeneic HSCT patients and healthy donors.
- To explore the expansion patterns of KIR+CD56+ T-cells and FcRg-CD56+CD3- NK cells in
response to viral infection and reactivation in pediatric allogeneic hematopoietic stem
cell transplant (HSCT) patients.
SECONDARY OBJECTIVES:
- To describe the phenotype of KIR+CD56+ T-cells and FcRg-CD56+CD3- NK cells in pediatric
allogeneic HSCT patients and healthy donors.
- To describe the specificity and functional capacity of KIR+CD56+ T-cells against viral
antigens in both pediatric allogeneic HSCT patients and healthy donors.
- To describe the functional capacity of FcRg-CD56+CD3- NK cells against CMV-infected
cells in both pediatric allogeneic HSCT patients and healthy donors.
Inclusion Criteria:
- Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for a
hematologic malignancy or a donor for a patient undergoing allogeneic hematopoietic
stem cell transplant for a hematologic malignancy.
- For HSCT patients: ages birth to 21 years old; for donors: any age.
- For minors less than 18 years old, both parents must be available on St. Jude campus
to provide consent. One parent/legal guardian will be acceptable if one parent is
deceased, incompetent, or when the one parent present has legal responsibility for
the care and custody of the child.
Exclusion Criteria:
- Patients undergoing allogeneic hematopoietic stem cell transplant for a disease other
than a hematologic malignancy
We found this trial at
1
site
262 Danny Thomas Pl
Memphis, Tennessee 38105
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Aimee Talleur, MD
Phone: 866-278-5833
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials
